Solution of carbon monoxide for the treatment of disease, including sickle cell disease

Abstract

The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.

1 . A method of treating a subject suffering from or at risk of developing a disease that is treatable with carbon monoxide (CO), said method comprising:
 administering to the subject a liquid composition comprising dissolved gaseous, or entrapped gaseous bubbles of, CO in an amount of 85 mg/l or more.   
     
     
         2 . The method of  claim 1 , wherein the liquid composition comprises dissolved gaseous, or entrapped gaseous bubbles of, CO in an amount of from 85 mg/l to 400 mg/l. 
     
     
         3 . The method of  claim 1 , wherein the volume of the liquid composition administered per day is 2 liters or less. 
     
     
         4 . The method of  claim 1 , wherein the volume of the liquid composition administered per day is 1 liter or less. 
     
     
         5 . The method of  claim 1 , wherein the administration is by way of the gastrointestinal tract. 
     
     
         6 . The method of  claim 5 , wherein administration by way of the gastrointestinal tract is by oral ingestion. 
     
     
         7 . The method of  claim 5 , wherein administration by way of the gastrointestinal tract is by rectal administration. 
     
     
         8 . The method of  claim 1 , wherein the administration is intravenous or subcutaneous. 
     
     
         9 . The method of  claim 1 , wherein the disease is: a hematological disease, an inflammatory disease, an ischemic disease, sepsis, a cardiovascular disease, kidney disease, liver disease, or a gastrointestinal disease. 
     
     
         10 . The method of  claim 9  wherein the ischemic disease is related to ischemia/reperfusion injury. 
     
     
         11 . The method of  claim 9 , wherein the hematological disease is caused by an abnormal hemoglobin. 
     
     
         12 . The method of  claim 9 , wherein the disease is Sickle Cell Disease, Hemoglobin C Disease, Hemoglobin SC Disease, or Hemoglobin S beta-thalassemia. 
     
     
         13 . The method of  claim 1 , wherein the disease is related to solid organ transplantation. 
     
     
         14 . The method of  claim 1 , wherein the disease is related to a burn injury. 
     
     
         15 . The method of  claim 1 , wherein administering is repeated one or more times to provide a treatment regimen. 
     
     
         16 . The method of  claim 1 , wherein the dissolved gaseous, or entrapped gaseous bubbles of, CO is present in an amount sufficient to prevent or treat at least one clinical symptom of a disease or disorder affected by CO. 
     
     
         17 . The method of  claim 1 , wherein the liquid composition further comprises at least one of: protein, lipid, fat, triglyceride, complex carbohydrate, sugar, artificial sugar substitute, fruit juice, carbohydrate, cellulose, fiber, citric acid, artificial flavoring, natural flavoring, gum, pectin, ascorbic acid, preservative, saponin, oil, oil emulsion, and a salt. 
     
     
         18 . The method of  claim 1 , wherein the liquid comprises water, ethanol, or both. 
     
     
         19 . The method of  claim 1 , wherein the liquid composition is a liquid colloidal dispersion, liquid suspension, emulsion, or foam. 
     
     
         20 . The method of  claim 1 , wherein the entrapped CO gas bubbles are present within the liquid composition when the liquid composition is at an ambient pressure environment.